Allelic variant in the glucagon‐like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study

Vijayvargiya, Priya; Carlson, Paula; Malderen, Kathleen Van; Acosta, Andrés; Zinsmeister, Alan R.; Camilleri, Michael

doi:10.1111/nmo.13313

Cited by 42 publications

(47 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It should be noted though, that according to Chedid and colleagues, there was no statistically significant difference in weight loss between wild type and polymorphic allele carriers after exenatide and liraglutide treatment. Nevertheless, researchers have found prolonged gastric emptying half-life in GA / AA genotypes [ 112 ].…”

Section: Genes Associated With Dpp4-inhibitors and Glp1 Receptor Amentioning

confidence: 99%

Pharmacogenetics of Type 2 Diabetes—Progress and Prospects

Nasykhova

Tonyan

Михайлова

et al. 2020

IJMS

View full text Add to dashboard Cite

Type 2 diabetes mellitus (T2D) is a chronic metabolic disease resulting from insulin resistance and progressively reduced insulin secretion, which leads to impaired glucose utilization, dyslipidemia and hyperinsulinemia and progressive pancreatic beta cell dysfunction. The incidence of type 2 diabetes mellitus is increasing worldwide and nowadays T2D already became a global epidemic. The well-known interindividual variability of T2D drug actions such as biguanides, sulfonylureas/meglitinides, DPP-4 inhibitors/GLP1R agonists and SGLT-2 inhibitors may be caused, among other things, by genetic factors. Pharmacogenetic findings may aid in identifying new drug targets and obtaining in-depth knowledge of the causes of disease and its physiological processes, thereby, providing an opportunity to elaborate an algorithm for tailor or precision treatment. The aim of this article is to summarize recent progress and discoveries for T2D pharmacogenetics and to discuss the factors which limit the furthering accumulation of genetic variability knowledge in patient response to therapy that will allow improvement the personalized treatment of T2D.

show abstract

Section: Genes Associated With Dpp4-inhibitors and Glp1 Receptor Amentioning

confidence: 99%

Pharmacogenetics of Type 2 Diabetes—Progress and Prospects

Nasykhova

Tonyan

Михайлова

et al. 2020

IJMS

View full text Add to dashboard Cite

show abstract

“…However, a further study in patients with poorly controlled T2DM found no statistical correlation between glp1r polymorphisms and GLP-1 responses [59]. Pharmacogenetic studies have additionally suggested a role for GLP-1R genetic variation in the extra-pancreatic effects of GLP-1RAs, including effects on gastric emptying [60] and cardiovascular safety of GLP-1RAs [61]. Selected glp1r SNPs have also been studied for changes associated with ligand-binding and signaling alterations [62].…”

Section: Polymorphisms Of the Glp1r Genementioning

confidence: 99%

New Insights into Beta-Cell GLP-1 Receptor and cAMP Signaling

Tomás

Jones

Leech

2020

Journal of Molecular Biology

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…The drug target gene GLP1R is the main focus in pharmacogenetic studies of GLP-1 receptor agonists. Some studies have shown that the carriers of the A allele in GLP1R rs6923761 have a propensity for a greater decrease in weight or a greater delay in GE after treatment with GLP-1 receptor agonists [88,89]. On the other hand, glycemic and weight response to exenatide have been consistently confirmed as an association with the GLP1R rs6923761 variant in overweight patients with T2D from China [90].…”

Section: Other Antidiabetic Agents and Associated Genesmentioning

confidence: 99%

“…However, another study indicates that GLP1R gene polymorphisms have no significant correlations with the response of treatment with GLP-1 analogue in patients with T2D [91]. In addition, the gene TCF7L2 rs7903146 variant also shows inconsistent results in pharmacogenetic studies of GLP-1 receptor agonists [88,92].…”

Section: Other Antidiabetic Agents and Associated Genesmentioning

confidence: 99%

Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes

2020

View full text Add to dashboard Cite

Diabetes is a major threat to people's health and has become a burden worldwide. Current drugs for diabetes have limitations, such as different drug responses among individuals, failure to achieve glycemic control, and adverse effects. Exploring more effective therapeutic strategies for patients with diabetes is crucial. Currently pharmacogenomics has provided potential for individualized drug therapy based on genetic and genomic information of patients, and has made precision medicine possible. Responses and adverse effects to antidiabetic drugs are significantly associated with gene polymorphisms in patients. Many new targets for diabetes also have been discovered and developed, and even entered clinical trial phases. This review summarizes pharmacogenomic evidence of some current antidiabetic agents applied in clinical settings, and highlights potential drugs with new targets for diabetes, which represent a more effective treatment in the future.

show abstract

Allelic variant in the glucagon‐like peptide 1 receptor gene associated with greater effect of liraglutide and exenatide on gastric emptying: A pilot pharmacogenetics study

Abstract: The minor A allele of GLP1R (rs6923761) is associated with greater delay in GE T in response to liraglutide and exenatide. These studies provide data to plan pharmacogenetics testing of the hypothesis that GLP1R (rs6923761) influences weight loss in response to GLP1R agonists.

Cited by 42 publications

References 26 publications

Pharmacogenetics of Type 2 Diabetes—Progress and Prospects

Pharmacogenetics of Type 2 Diabetes—Progress and Prospects

New Insights into Beta-Cell GLP-1 Receptor and cAMP Signaling

Pharmacogenomic Studies of Current Antidiabetic Agents and Potential New Drug Targets for Precision Medicine of Diabetes

Contact Info

Product

Resources

About